Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density.

Abstract

OBJECTIVE:

To establish whether treatment for three years with pro-juven progesterone cream affects progression of atherosclerotic plaques or bone density in postmenopausal women. Design Randomized double-blind placebo-controlled trial. Sample One hundred and thirty-one healthy postmenopausal women aged between 50 and 75 years with at least one asymptomatic arterial plaque visible on ultrasound of the carotid or femoral bifurcation.

METHODS:

Women were randomly allocated to receive pro-juven progesterone cream, 20 mg twice daily, or placebo, for three years. Main outcome measure Rate of change of plaque thickness, intima-media thickness and bone density of lumbar spine and femoral neck.

RESULTS:

There was no difference between the groups.

CONCLUSION:

Pro-juven progesterone cream 20 mg twice daily did not affect progression of asymptomatic atherosclerosis or deterioration in bone density over three years.

• Authors: Beverly Benster, Adam Carey, Fred Wadsworth, Maura Griffin, Andrew Nicolaides, John Studd
• Journal: Menopause international (Menopause Int) Vol. 15 Issue 3 Pg. 100-6 (Sep 2009) ISSN: 1754-0453 [Print] England
• PMID: 19723679 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ointments
• Placebos
• Progesterone

Topics

• Administration, Topical
• Aged
• Atherosclerosis (drug therapy)
• Double-Blind Method
• Female
• Hormone Replacement Therapy
• Humans
• Middle Aged
• Ointments
• Osteoporosis, Postmenopausal (drug therapy)
• Placebos
• Progesterone (administration & dosage)
• Treatment Outcome